A gene signal linked to shorter survival in glioblastoma
Original title: miR-1289 promotes glioblastoma tumorigenesis via targeting EFNA5.
How far along is this research?
- Lab cells
- Animals
- Review
- Tested in people
This was done on cells in a lab, not in people. It is a very early step.
This was mostly done on cells in a lab, not tested as a treatment in people.
The short version
Lab work found a small gene signal that may help glioblastoma: A glioma that is given grade 4, the highest grade. It grows fast. Treatment usually starts soon after it is found. It often means surgery, then radiation and chemotherapy. See the glossary grow.
What was studied. Researchers looked at glioblastoma: A glioma that is given grade 4, the highest grade. It grows fast. Treatment usually starts soon after it is found. It often means surgery, then radiation and chemotherapy. See the glossary tumors and at tumor cells grown in a lab dish. They measured a small gene signal called miR-1289 and a gene called EFNA5.
What they found. miR-1289 levels were high in glioblastoma: A glioma that is given grade 4, the highest grade. It grows fast. Treatment usually starts soon after it is found. It often means surgery, then radiation and chemotherapy. See the glossary. Patients with high levels lived a shorter time. When the researchers lowered miR-1289, the tumor cells grew, moved, and spread less in the dish. The signal worked by turning down the EFNA5 gene.
What this means, and what it doesn't
What it could mean: This might one day help doctors judge how a tumor is likely to act. It is a possible marker, not a treatment. Nothing about care changes today.
What it doesn't mean: This does not mean there is a new drug, and it is not a cure. Most of this work was done on cells in a lab dish. No one has tested this as a treatment in people. It is early science and is far from everyday care.
Source: PubMed, September 3, 2026 · Read the original
This plain-language summary was written by AI and published automatically after passing our automatic safety checks. How we write.